Marshall Wace’s enVVeno Medical NVNO Stock Holding History

Marshall Wace’s Portfolio NVNO Stock Details NVNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,140	Closed	-$36.3K	–	3322
2025 Q3	$36.3K	Buy	+1,140	New	+$116K	﹤0.01%	2749
2025 Q1	–	Sell	-1,395	Closed	-$147K	–	2954
2024 Q4	$147K	Buy	+1,395	New	+$156K	﹤0.01%	2402
2024 Q2	–	Sell	-1,146	Closed	-$218K	–	2829
2024 Q1	$218K	Buy	1,146 +709	+162%	+$127K	﹤0.01%	2210
2023 Q4	$78.6K	Buy	+437	New	+$69.6K	﹤0.01%	2058
2021 Q4	–	Sell	-349	Closed	-$127K	–	4168
2021 Q3	$127K	Buy	+349	New	+$90.4K	﹤0.01%	2858

Other funds holding NVNO

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Marshall Wace's NVNO Position: Q4 2025 in Review

Marshall Wace sold out of enVVeno Medical (NVNO) in Q4 2025, closing a stake of 1,140 shares — an estimated $36.3K sold.

Marshall Wace first reported a position in NVNO in Q3 2021 and held it in 5 quarters. The position peaked at $218K in Q1 2024. 36 funds tracked by Wall St. Rank hold NVNO as of Q4 2025.

Marshall Wace reported no remaining enVVeno Medical position as of Q4 2025 after selling out during the quarter.
Marshall Wace sold 1,140 enVVeno Medical shares in Q4 2025, an estimated $36.3K.
Marshall Wace first reported a position in enVVeno Medical in Q3 2021 and held it in 5 quarters.
Marshall Wace's enVVeno Medical position peaked at $218K in Q1 2024.
36 funds tracked by Wall St. Rank held enVVeno Medical as of Q4 2025.

Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.